List of Excipients in Branded Drug CARBINOXAMINE MALEATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	ANHYDROUS CITRIC ACID
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	GLYCERIN
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	HIGH FRUCTOSE CORN SYRUP
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	METHYLPARABEN
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	POLYSORBATE 80
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	POVIDONE
Neos Therapeutics LP	CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION	carbinoxamine maleate	62542-101	PROPYLPARABEN

Generic Drugs Containing CARBINOXAMINE MALEATE

Company	Ingredient	NDC	Excipient
Biocomp Pharma Inc	carbinoxamine maleate	44523-825	ANHYDROUS LACTOSE
Biocomp Pharma Inc	carbinoxamine maleate	44523-825	CELLULOSE, MICROCRYSTALLINE
Biocomp Pharma Inc	carbinoxamine maleate	44523-825	MAGNESIUM STEARATE
Biocomp Pharma Inc	carbinoxamine maleate	44523-825	SODIUM STARCH GLYCOLATE TYPE A CORN
Mikart LLC	carbinoxamine maleate	46672-191	ANHYDROUS LACTOSE
Mikart LLC	carbinoxamine maleate	46672-191	CELLULOSE, MICROCRYSTALLINE
Mikart LLC	carbinoxamine maleate	46672-191	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CARBINOXAMINE MALEATE?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
9	ANHYDROUS LACTOSE
9	CELLULOSE, MICROCRYSTALLINE
1	GLYCERIN
9	MAGNESIUM STEARATE
1	METHYLPARABEN
1	PROPYLENE GLYCOL

Excipient Strategy and Commercial Opportunities for CarbinoXamine Maleate

Last updated: February 26, 2026

What is the optimal excipient strategy for CarbinoXamine Maleate?

CarbinoXamine Maleate is a synthetic antihistamine with applications in allergy relief. Its formulation requires careful selection of excipients to improve stability, bioavailability, and patient acceptability. Basic excipient roles include acting as fillers, binders, disintegrants, lubricants, and stabilizers.

Key excipient considerations

• Stability: Maleate salts can degrade via hydrolysis or oxidation; antioxidants like ascorbic acid may be used.
• Solubility: Enhancing solubility may necessitate surfactants (e.g., sodium lauryl sulfate) or solubilizers.
• Bioavailability: Incorporation of bioavailability enhancers (e.g., cyclodextrins) can improve absorption.
• Taste masking: Flavors and sweeteners like saccharin provide palatability.

Common excipients for formulation

Exipient Type	Function	Examples	Notes
Fillers	Volume expansion	Microcrystalline cellulose, lactose	Increases drug mass for tableting
Binders	Maintain tablet integrity	Polyvinylpyrrolidone, starch	Prevents separation during compression
Disintegrants	Facilitate tablet breakup	Croscarmellose sodium, sodium starch glycolate	Improve dissolution rate
Lubricants	Ease manufacturing	Magnesium stearate, stearic acid	Reduce tablet sticking to equipment
Stabilizers	Prolong shelf life	Ascorbic acid, antioxidants	Prevent oxidative degradation

What are the commercial opportunities for CarbinoXamine Maleate?

The drug's market includes immediate-release formulations for allergy treatment, with potential for expansion into sustained-release, transdermal, or combination therapies.

Market drivers

• Growing allergy prevalence: US prevalence exceeds 50 million cases annually (American College of Allergy, Asthma, and Immunology, 2022).
• Patient preference for oral formulations: Ease of administration encourages oral tablet and capsule development.
• Emerging indications: Off-label uses for allergic rhinitis alongside environmental triggers.

Competitive landscape

• Existing products: Loratadine, cetirizine, and fexofenadine dominate the market, with global sales exceeding $10 billion (IQVIA, 2022).
• Differentiation opportunities:
  • Lower side-effect profile
  • Faster onset
  • Reduced drowsiness potential

Regulatory pathway considerations

• FDA approval: Requires demonstrating bioequivalence or clinical superiority.
• Patent landscape: Patent expiry for similar drugs from 2025 onwards opens pathways for generic development.

Commercial strategies

• Formulation innovation: Developing novel delivery systems like orodispersible tablets or transdermal patches.
• Manufacturing scalability: Optimizing excipient blends for cost-effective large-scale production.
• Partnerships: Collaborating with contract manufacturing organizations (CMOs) to reduce time-to-market.

What are the challenges in excipient selection and commercialization?

• Regulatory constraints: Stringent excipient safety testing and batch consistency.
• Stability issues: Maleate salts may require proprietary stabilization techniques.
• Market saturation: Presence of established generic brands limits pricing power.
• Patient compliance: Taste masking and formulation acceptability are critical for pediatric markets.

Key Takeaways

• A balanced excipient strategy for CarbinoXamine Maleate involves stabilizers, solubility enhancers, and taste-masking agents.
• Market opportunity hinges on differentiation through formulation innovation and regulatory positioning.
• Strategic partnerships and cost-optimized manufacturing support commercialization.
• Challenges include regulatory hurdles, stability complexities, and intense market competition.

FAQs

1. What excipients are best suited for improving CarbinoXamine Maleate stability?
   Antioxidants such as ascorbic acid or tocopherols are commonly used, alongside proper packaging to minimize hydrolysis and oxidation.

2. Can CarbinoXamine Maleate be formulated as a transdermal patch?
   Yes, research indicates potential for transdermal delivery systems utilizing permeation enhancers and suitable excipients to bypass gastrointestinal degradation.

3. What are the regulatory considerations for excipient use in CarbinoXamine Maleate formulations?
   Regulatory agencies require safety data, manufacturing controls, and compatibility studies to approve excipients, especially for pediatric or long-term use.

4. Are there opportunities for combination products involving CarbinoXamine Maleate?
   Combination therapies with other antihistamines or decongestants can address broader allergy symptom profiles, expanding market reach.

5. What differentiates successful formulation strategies in this market?
   Innovations that improve onset time, reduce side effects, and enhance patient compliance while maintaining cost-effectiveness drive product success.

References

1. American College of Allergy, Asthma, and Immunology. (2022). Allergy prevalence statistics. https://acaai.org
2. IQVIA. (2022). Global antihistamine market analysis. https://iqvia.com